ES2921224R1 - Metodo in vitro para el diagnostico diferencial entre pacientes con shock septico y no septico - Google Patents

Metodo in vitro para el diagnostico diferencial entre pacientes con shock septico y no septico

Info

Publication number
ES2921224R1
ES2921224R1 ES202290051A ES202290051A ES2921224R1 ES 2921224 R1 ES2921224 R1 ES 2921224R1 ES 202290051 A ES202290051 A ES 202290051A ES 202290051 A ES202290051 A ES 202290051A ES 2921224 R1 ES2921224 R1 ES 2921224R1
Authority
ES
Spain
Prior art keywords
septic
patients
vitro method
differential diagnosis
septic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES202290051A
Other languages
English (en)
Other versions
ES2921224A2 (es
Inventor
Gomez Eduardo Tamayo
Moran Emilio Garcia
Rodriguez María Heredia
Sanchez Esther Gomez
De Paz Pedro José Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gerencia Regional De Salud De Castilla Y Leon
Universidad de Valladolid
Original Assignee
Gerencia Regional De Salud De Castilla Y Leon
Universidad de Valladolid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerencia Regional De Salud De Castilla Y Leon, Universidad de Valladolid filed Critical Gerencia Regional De Salud De Castilla Y Leon
Publication of ES2921224A2 publication Critical patent/ES2921224A2/es
Publication of ES2921224R1 publication Critical patent/ES2921224R1/es
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Retarders (AREA)
ES202290051A 2019-12-20 2020-12-18 Metodo in vitro para el diagnostico diferencial entre pacientes con shock septico y no septico Pending ES2921224R1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383174 2019-12-20
PCT/EP2020/087145 WO2021123249A1 (en) 2019-12-20 2020-12-18 In vitro method for the differential diagnosis between septic shock and non-septic shock patients

Publications (2)

Publication Number Publication Date
ES2921224A2 ES2921224A2 (es) 2022-08-22
ES2921224R1 true ES2921224R1 (es) 2023-05-12

Family

ID=69167586

Family Applications (1)

Application Number Title Priority Date Filing Date
ES202290051A Pending ES2921224R1 (es) 2019-12-20 2020-12-18 Metodo in vitro para el diagnostico diferencial entre pacientes con shock septico y no septico

Country Status (2)

Country Link
ES (1) ES2921224R1 (es)
WO (1) WO2021123249A1 (es)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220129A1 (en) * 2017-05-31 2018-12-06 B.R.A.H.M.S Gmbh Mmp-8 as a marker for identifying infectious disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
ES2506116T3 (es) * 2008-05-23 2014-10-13 Biocartis Nv Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
US9267175B2 (en) * 2012-02-07 2016-02-23 Children's Hospital Medical Center Multi-biomarker-based outcome risk stratification model for adult septic shock
EP3221452A4 (en) * 2014-11-21 2018-11-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN106093416B (zh) * 2016-05-18 2018-10-12 北京北方生物技术研究所有限公司 一种一步法检测降钙素原的试剂盒及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220129A1 (en) * 2017-05-31 2018-12-06 B.R.A.H.M.S Gmbh Mmp-8 as a marker for identifying infectious disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALMANSA R. ET AL. Quantification of immune dysregulation by next-generation polymerase chain reaction to improve sepsis diagnosis in surgical patients. Ann Surg, 03/2019, Vol. 269, Páginas 545-553 *
ALMANSA R. ET AL. Transcriptomic correlates of organ failure extent in sepsis. Journal of Infection. 31/12/2014, Vol. 70, Páginas 445-456 todo el documento *
HU W-C. Sepsis is a Syndrome with Hyperactivity of TH17-Like Innate Immunity and Hypoactivity of Adaptive Immunity. arXiv, 19/11/2013, *
HU W-C. Sepsis is a Syndrome with Hyperactivity of TH17-Like Innate Immunity and Hypoactivity of Adaptive Immunity. arXiv, 19/11/2013, página 2 página 12 página 15 página 20 página 23 página 44 página 52 página 64 *

Also Published As

Publication number Publication date
ES2921224A2 (es) 2022-08-22
WO2021123249A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
DK3737765T3 (da) Forstærkede immunceller med dobbelt shrna og sammensætning dermed
EP3958732A4 (en) METHODS AND SYSTEMS FOR ASSESSING INFLAMMATORY DISEASE WITH DEEP LEARNING
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
MX2015012933A (es) Micrordenamiento para suministro de agente terapeutico y metodos de uso.
EP3292406A4 (en) INTERFEROMETRIC SYSTEM AND METHOD FOR USE WITH BIOLOGICAL CELLS AND ORGANISMS, INCLUDING SPERM
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
IL274265A (en) A variant and isoform of an antibody with attenuated biological activity
EP3186397C0 (en) USE OF BIOMARKERS OF CIRCULATING CELLS IN THE BLOOD FOR THE DETECTION AND DIAGNOSIS OF DISEASES, AND THEIR ISOLATION PROCESSES
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
PE20151893A1 (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
EP3539337A4 (en) AVOIDANCE OF EMBMS COMPETITION WITH CALLS IN NB-IOT AND EMTC
CL2017000608A1 (es) Cubiertas enrollables para aberturas arquitectónicas y métodos, sistemas y dispositivos relacionados
CL2016002945A1 (es) Método de cultivo in vitro para aumentar la biomasa y aumentar el número de plántulas de variedades y portainjertos de prunus spp., particularmente prunus avium.
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
IL281389A (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
EP3280363A4 (en) Inflatable perfusion balloon with outer mesh and related methods
UY37534A (es) Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda
CL2020000734A1 (es) Expansión y uso de fracciones de células nk ampliadas.
ES2921224R1 (es) Metodo in vitro para el diagnostico diferencial entre pacientes con shock septico y no septico
CO2017007669A2 (es) Películas envolventes con opacidad aumentada
CL2018001138A1 (es) Un método ex vivo para probar la respuesta celular de las poblaciones de células primarias a una droga o combinación de drogas
EP3304041A4 (en) Methods of assessing cellular breast samples and compositions for use in practicing the same
GB201900797D0 (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
EP3717912A4 (en) METHODS AND MATERIALS FOR EVALUATING BIOLOGICAL AGE AND SLOWING THE PROGRESS OF EXCESSIVE BIOLOGICAL AGING

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2921224

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20220822

EC2A Search report published

Ref document number: 2921224

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20230505